by HAEMATO AG | Mar 29, 2021 | Ad-Hoc Announcement
HAEMATO AG (ISIN: DE000A289VV1, WKN: A289VV) has successfully completed the capital increase which was announced on March 24, 2021. The capital increase was oversubscribed. The Company increased its share capital by € 475,391.00 to € 5,229,307.00 by issuing a total of... 
by HAEMATO AG | Mar 24, 2021 | Ad-Hoc Announcement
HAEMATO AG plans cash capital increase to finance private label businessHAEMATO AG resolves to carry out a cash capital increase using the Authorized Capital 2018 with exclusion of subscription rights in the amount of up to 10% of the share capital to finance the... 
by HAEMATO AG | Mar 23, 2021 | Ad-Hoc Announcement
Ad hoc of HAEMATO AG:HAEMATO PHARM GmbH as a subsidiary of HAEMATO AG (symbol: HAEK) received a special approval in accordance with § 11 Para. 1 MPG from the Federal Institute for Drugs and Medical Devices ( BfArM) for the antigen rapid test for self-testing by... by HAEMATO AG | Feb 1, 2021 | Ad-Hoc Announcement
Patrick Brenske to be the sole member of the Executive Board of HAEMATO AG in the future Patrick Brenske, member of the Executive Board of HAEMATO AG since November 30, 2020 and Head of Purchasing and Sales of the HAEMATO Group for approximately eight years until... 
by HAEMATO AG | Dec 15, 2020 | Ad-Hoc Announcement, Investor News
HEMATO AG acquires “M1 Aesthetics GmbH” from M1 Kliniken AG – Contribution of the company within the scope of a capital increase in kind of HAEMATO AG Berlin, 15.12.2020 – M1 Kliniken AG and HAEMATO AG today signed a contract for the... 
by HAEMATO AG | Nov 30, 2020 | Ad-Hoc Announcement, Investor News
HAEMATO AG: Expansion of the board of directors: Strengthening the strategic and operative implementation of the product business in the Haemato Group Schönefeld, 30.11.2020 – The supervisory board of HAEMATO AG has appointed Mr. Patrick Brenske to the board of...
